Study of ZG005 in Patients With Advanced Solid Tumors
Intervencionista
Fase 2
Sun Yat-sen University Cancer Center
Patrocinador: Zelgen Biopharmaceuticals
Última actualización: 5 de enero de 2026 Aviso: La información proviene de registros públicos y puede no reflejar cambios en tiempo real en el centro local.
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
* Life expectancy ≥ 12 weeks;
* Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Criterios de exclusión
* Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
* Any other malignancy within 5 years.
¿Cree usted que este ensayo clínico se muestra por error?
Detalles del diseño
AsignaciónN/A
Modelo de intervenciónSingle Group Assignment
EnmascaramientoNone (Open Label)
Número a inscribir100
Brazos e Intervenciones
Brazos
Intervenciones
Tipo: Experimental
Descripción: ZG005 dose expansion was performed in different tumors, such as: nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and other carcinoma
Intervenciones:
ZG005 for Injection
Medidas de resultado
Medidas de resultado primarias
Objective response rate(ORR)Up to 2 years
Medidas de resultado secundarias
Adverse Event (AE)Up to 2 years
Guardar ensayo
Compartir ensayo
Descargar ensayo
¿Cree usted que este ensayo clínico se muestra por error?